Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.

ABSTRACT:

Background

Osteosarcoma is the most common malignant solid tumor that affects bones, however, survival rates of patients with relapsed osteosarcoma have not improved in the last 30 years. Oncolytic virotherapy, which uses viruses designed to selectively replicate in cancer cells, has emerged as a promising treatment for solid tumors. Our group uses mesenchymal stem cells (MSCs) to transport oncolytic adenoviruses (OAds) to the tumor site, a therapeutic strategy called Celyvir. This treatment has been already applied in human patients, canine patients and different mouse models. In parallel, previous results have probed that administration of granulocyte-colony stimulating factor (G-CSF) increased immune infiltration in tumors. We then hypothesized that the mobilization of immune ce

SUBMITTER: Morales-Molina A 

PROVIDER: S-EPMC7978281 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature